DarioHealth Corp. (DRIO)
| Market Cap | 14.11M -85.1% |
| Revenue (ttm) | 21.30M -13.9% |
| Net Income | -6.57M |
| EPS | -0.68 |
| Shares Out | 9.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,858 |
| Open | 1.670 |
| Previous Close | 1.460 |
| Day's Range | 1.440 - 1.753 |
| 52-Week Range | 1.090 - 14.770 |
| Beta | 1.18 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+455.56%) |
| Earnings Date | Nov 12, 2026 |
About DRIO
DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a behavioral health offering that decreases the sympt... [Read more]
Financial Performance
In 2025, DarioHealth's revenue was $22.36 million, a decrease of -17.31% compared to the previous year's $27.04 million. Losses were -$40.31 million, 34.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for DRIO stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 455.56% from the latest price.
News
DarioHealth, WebMD Health Services announce strategic partnership
DarioHealth (DRIO) announced a strategic partnership with WebMD Health Services. Dario expects the partnership to begin contributing annual recurring revenue in 2027, including via distribution throug...
Dario and WebMD Health Services Announce Strategic Partnership to Deliver Dario's Multi-Condition Platform to Millions of Covered Lives
Extends Dario's reach to WebMD Health Services' 3,500 employers and 65 million lives covered Partnership combines WebMD ONE, a trusted engagement platform, with Dario's comprehensive AI-powered multi-...
Dario Secures Second Women's Health Contract in Just Weeks with The Minnesota Star Tribune
New agreement reflects rapid adoption of recently launched Dario Women™, the Company's women's health solution addressing perimenopause and menopause The Minnesota Star Tribune expands its existing re...
DarioHealth price target lowered to $11 from $12 at Alliance Global
Alliance Global lowered the firm’s price target on DarioHealth (DRIO) to $11 from $12 and keeps a Buy rating on the shares. The firm cites its lowered forecasts post the…
Dario Presents New Research at ISPOR Europe 2026 Validating a Biometric-Driven Approach to Estimating Healthcare Cost Savings and ROI - Consistent with Published Benchmarks and Without Waiting for Claims Data
New methodology addresses critical market need for a transparent, replicable model to estimate healthcare cost savings and ROI when medical claims data are unavailable or delayed Further demonstrates ...
DarioHealth price target lowered to $5 from $10 at Stifel
Stifel lowered the firm’s price target on DarioHealth (DRIO) to $5 from $10 and keeps a Buy rating on the shares.
DarioHealth Earnings Call Transcript: Q3 2026
Q3 revenue grew 6% YoY, with operating expenses and losses lower. Management expects ARR conversion to drive revenue acceleration through 2027 and targets break-even in 2028, while expanding channel, multi-condition and GLP-1 opportunities.
DarioHealth Quarterly report: Q3 2026
DarioHealth has published its Q3 2026 quarterly earnings report on November 12, 2026.
DarioHealth Earnings release: Q3 2026
DarioHealth released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
DarioHealth Slides: Investor presentation
DarioHealth has posted slides in relation to its latest quarterly earnings report, which was published on November 12, 2026.
DarioHealth reports Q3 EPS (73c), consensus (51c)
Reports Q3 revenue $5.31M, consensus $5.21M. “In the second quarter of 2026, we described how Dario’s business model is designed to support growth. We believe that our third quarter of…
DarioHealth Reports Third Quarter 2026 Financial Results: Year-over-Year Revenue Growth and Operating Expense Reduction
Third quarter 2026 revenue increased 6% year-over-year and 3% sequentially to $5.3 million GAAP gross margin was 59%, compared to 60% in the third quarter of 2025; non-GAAP business-to-business-to-con...
Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care
Mr. Palumbo to join Dario's third quarter 2026 earnings call to share the Board's view on the convergence of consumer and payer-led healthcare and chronic care management NEW YORK, Nov. 4, 2026 /PRNew...
DarioHealth to Report Third Quarter 2026 Results on Thursday, November 12, 2026
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Nov. 2, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leading artificial intellige...
DarioHealth Slides: Corporate presentation
DarioHealth has posted slides in relation to its latest quarterly earnings report, which was published on October 29, 2026.
DarioHealth initiated with a Buy at BTIG
BTIG analyst David Larsen initiated coverage of DarioHealth (DRIO) with a Buy rating and $6 price target The firm says DarioHealth is a multi-condition, vertically integrated digital health platform w...
DarioHealth extends contract with regional grocery retailer for women’s health
DarioHealth (DRIO) announced that a regional grocery retailer client has expanded its contract with Dario to add Dario Women, the company’s recently launched women’s health solution supporting women n...
Dario Expands Contract with a Leading Regional Grocery Retailer, Adding Women's Digital Health and Clinical Care Program
Contract extension follows benefits realized from Dario's cardiometabolic program and strong employee demand for perimenopause support Nearly 45% of Dario's current book of business is women over age ...
DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs
A component study of the independent review by Aon found $5,077 in annual savings and 23.5% fewer inpatient discharges per Dario user with type 2 diabetes versus matched non-users Evaluation of 17 stu...
DarioHealth announces new contract with health plan in New Jersey
DarioHealth (DRIO) announced a new contract with a leading health plan in New Jersey, one of the largest in the state representing approximately 1.5M covered lives. The agreement was secured…
Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives
Agreement secured through channel partner Amwell significantly expands Dario's reach through its channel distribution strategy Program for Dario's cardiometabolic suite and provider-backed care expect...
DarioHealth initiated with a Buy at Alliance Global
Alliance Global analyst Scott Henry initiated coverage of DarioHealth (DRIO) with a Buy rating and $12 price target DarioHealth is a vertically integrated health intelligence platform that is utilized...
DarioHealth price target lowered to $8 from $11 at TD Cowen
TD Cowen lowered the firm’s price target on DarioHealth (DRIO) to $8 from $11 and keeps a Hold rating on the shares. The firm updated its model following softer Q2…
DarioHealth trading halted, volatility trading pause
09:57 EDT DarioHealth (DRIO) trading halted, volatility trading pause
